SCHEMBL3154124

SCHEMBL3154124

COCCNCc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOC P08134 2/20 0.49
RHOA P61586 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.45
SCN8A Q9UQD0 2/20 0.45
TACR1 P25103 2/20 0.43
IDO1 P14902 2/20 0.42
MTOR P42345 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MLYCD O95822 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
GAA P10253 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GPBAR1 Q8TDU6 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20776842 0.83 SCN8A (0.57) L3MBTL1SCN8AIDO1MEN1KMT2A
SCHEMBL5084706 0.79 TACR1 (0.59) RHOCRHOATACR1IDO1MTOR
SCHEMBL4713071 0.79 SCN8A (0.53) L3MBTL1SCN8AMEN1KMT2AALDH1A1
SCHEMBL6948873 0.77 RHOC (0.57) RHOCRHOASCN8ATACR1IDO1
SCHEMBL6991073 0.77 RHOC (0.56) RHOCRHOASCN8ATACR1IDO1
SCHEMBL4260305 0.77 RHOC (0.53) RHOCRHOASCN8ATACR1IDO1
SCHEMBL13995257 0.76 XPO1 (0.51) RHOCRHOASCN8ATACR1IDO1
SCHEMBL1587762 0.76 TACR1 (0.49) RHOCRHOASCN8ATACR1IDO1
SCHEMBL5779082 0.76 IDO1 (0.48) TACR1IDO1ALDH1A1CYP1A2CYP2D6
SCHEMBL4256377 0.74 RHOC (0.57) RHOCRHOASCN8ATACR1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513814-B1 NOVEL PIPERIDINE COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2010-03-17 EP disclosed
US-7619092-B2 Piperidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-11-17 US disclosed
EP-1513814-A4 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO (JP) 2007-03-14 EP disclosed
US-20050239829-A1 Novel piperidine compound TANABE SEIYAKU CO. LTD. (JP) 2005-10-27 US disclosed
EP-1513814-A1 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-03-16 EP disclosed
WO-2003099787-A1 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239829-A1 Novel piperidine compound EP300, BRD1, CBR3 RHOC 2127/4885RHOA 4427/4885L3MBTL1 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.